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Traumatic brain injury (TBI) is a mechanical insult to the brain caused by external forces 
and associated with inflammation and oxidative stress. The patients may show different 
profiles of neurological recovery and a combination of oxidative damage and inflamma-
tory processes can affect their courses. It is known that an overexpression of cytokines 
can be seen in peripheral blood in the early hours/days after the injury, but little is known 
about the weeks and months encompassing the post-acute and chronic phases. In 
addition, no information is available about the antioxidant responses mediated by the 
major enzymes that regulate reactive oxygen species levels: superoxide dismutase, 
catalase, peroxidases, and GSH-related enzymes. This study investigates the 6-month 
trends of inflammatory markers and antioxidant responses in 22 severe TBI patients with 
prolonged disorders of consciousness, consecutively recruited in a dedicated neurore-
habilitation facility. Patients with a high degree of neurological impairment often show an 
uncertain outcome. In addition, the profiles of plasma activities were related to the neu-
rological recovery after 12 months. Venous peripheral blood samples were taken blindly 
as soon as clinical signs and laboratory markers confirmed the absence of infections, 
3 and 6 months later. The clinical and neuropsychological assessment continued up to 
12 months. Nineteen patients completed the follow-up. In the chronic phase, persistent 
high plasma levels of cytokines can interfere with cognitive functioning and higher post-
acute levels of cytokines [interferon (IFN)-γ, tumor necrosis factor (TNF)-α, IL1b, IL6] are 
associated with poorer cognitive recoveries 12 months later. Moreover, higher IFN-γ, 
higher TNF-α, and lower glutathione peroxidase activity are associated with greater dis-
ability. The results add evidence of persistent inflammatory response, provide information 
about long-term imbalance of antioxidant activity, and suggest that the over-production 
of cytokines and the alteration of the redox homeostasis in the post-acute phase might 
adversely affect the neurological and functional recovery. Inflammatory and antioxidant 
activity markers might offer a feasible way to highlight some of the processes opposing 
recovery after a severe TBI.
Keywords: traumatic brain injury, inflammation, oxidative stress, cytokines plasma levels, follow-up, cognitive 
outcome
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inTrODUcTiOn
Traumatic brain injury (TBI) is a mechanical insult to the brain 
caused by external forces resulting in temporary or permanent 
neurological deficits. TBI is a disorder with major health impact, 
since it may often result in lifelong impairments of physical, 
cognitive, and psychosocial functioning (1). Moreover, TBI is one 
of the leading causes of disability in children and young adults.
After a TBI, the brain damages occur in two distinct phases: 
the primary injury is caused immediately by the mechanical 
forces acting on the skull and the brain and the secondary 
injury consists in a cascade of events sustained by other 
mechanisms, such as ischemia, hypoxemia, and raised intrac-
ranial pressure. The secondary injury occurs progressively in 
minutes/hours after the primary injury and the resulting brain 
damages are exacerbated by oxidative stress, inflammation, 
and excitotoxicity (2).
Recent reports suggest that inflammation is associated with 
TBI (3, 4), and cerebral inflammatory responses appear to begin 
within minutes after TBI (5). In addition, high levels of inflamma-
tory cytokines, such as interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, 
IL-10, tumor necrosis factor (TNF)-α and interferon (IFN)-γ, 
have been reported in human postmortem brain tissue (5).
Oxidative stress occurs when the brain antioxidant mecha-
nisms are overcome by increasing levels of reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS) (6). The oxidative 
stress plays a complex role in the mechanisms of damage after 
TBI (6, 7). The brain consumes about 20–30% of inspired oxygen, 
and contains high levels of polyunsaturated fatty acids and redox 
transition metals, and, therefore, is a vulnerable target for ROS 
attack (8). Brian intense metabolic activity, extensive production 
of ROS, reduced antioxidant capacity, and low levels of repair 
mechanisms in neurons may influence brain high susceptibility 
to oxidative stress (9). The abnormal ROS production downregu-
lates tight junction proteins and activates matrix metalloprotein-
ases (MMPs) that contribute to impair the blood–brain barrier 
(BBB) permeability.
Brain cells may use different types of antioxidants, including 
enzymes and low-molecular weight antioxidants. Superoxide 
dismutase (SOD), catalase (CAT), peroxidases, and GSH-related 
enzymes are the major enzymes that regulate ROS levels. The ROS 
are able to directly induce the synthesis and release of inflamma-
tory cytokines, such as IL-1β and TNF-α (6).
These events are not confined to the first acute period after 
TBI injury. Pro-inflammatory molecules are released by activated 
microglia after TBI (10), and there is still evidence of increased 
microglial activity years after the brain traumatic event (11–13).
The presence of the allele 4 of the apolipoprotein E (APOE) 
gene, a known genetic risk factor for Alzheimer’s disease (AD), 
affects the progression of neurodegenerative processes in TBI 
patients (14) and is associated with increased neurologic com-
plications (15).
Severe TBI has various sequelae with a wide range of sever-
ity. Similar injuries may greatly differ in clinical presentation 
and long-term outcome. After a severe TBI, people have been 
considered “survivors” facing permanent deficits, but the clinical 
evidence suggests that the TBI is not a pure traumatic event (16), 
since patients show different time and rate of recovery, or may 
result in progressive clinical deterioration.
Progressive white matter deterioration can persist for 1–2 years 
(17–21) or even for longer time intervals (22, 23).
The cognitive functioning after 1 year (24) or after 2–5 years 
(25) in 30% of the patients may worsen, and an increased inci-
dence of AD and Parkinson’s disease has been associated with 
TBI (26).
The mechanisms underlying the outcome and history of 
functioning after severe TBI are complex and neuroinflamma-
tion and neurodegeneration may have a prominent role, as well 
as neuroplasticity and rewiring. The mechanisms underlying the 
neurodegeneration after a TBI are still not completely elucidated, 
but they might include a combination of oxidative damage and 
inflammatory processes.
Several studies have addressed the question whether the 
plasma inflammatory markers may offer clinically valuable infor-
mation after TBI. Most studies describe increased serum levels of 
cytokines (mainly IL-6, IL-8, IL-10, and TNF-α) in serum shortly 
after the injury, i.e., hours to days (up to 5 days) (27–35). A small 
number of studies have investigated inflammatory factors during 
slightly longer periods such as 7 days (36, 37), 14 days (38), or 
22 days (39). Only one study (40) has reported elevated serum 
levels of IL-1β, IL-6, IL-8, IL-10, and TNF-α in TBI patients’ 
blood samples taken during the subacute and the chronic phase 
(3–6 months) after the injury.
The present investigation explores the hypothesis that persis-
tently high inflammatory responses may be associated with a slow 
or poor cognitive recovery and increased odds of late worsening. 
To validate the above notion 6-month trends of oxidative stress 
and inflammatory factors in the post-acute and chronic phases 
after a severe TBI have been investigated. Moreover, plasma 
profiles of oxidative stress-related enzymes and inflammatory 
makers have been related to the cognitive performances and 
recovery attained 12 months after TBI.
MaTerials anD MeThODs
subjects
Twenty-two patients with diagnosis of coma, vegetative state (SV), 
or minimally conscious state (MCS) were consecutively enrolled 
after they were transferred from the intensive care unit (ICU) to 
the neurorehabilitation unit of the Emergency Department, at the 
Maggiore Hospital in Bologna.
This study was approved by the Independent Ethics 
Committee of Bologna and was carried out according to the 
Helsinki Declaration (cod. CE 11076/2012), and a proxy consent 
was signed by a representative of each patient.
Patients with neurodegenerative diseases, history of clinical 
depression, other psychiatric disorders, and autoimmune and/
or severe metabolic disorders were not included. Patients with 
previous motor or cognitive disabilities were also not included. 
Before the TBI, all subjects were able to carry out all usual duties 
and activities.
Structural damages along with secondary clinical and surgi-
cal complications of the neurological trauma were carefully 
recorded.
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All patients (age range 18–65  years) suffered from a severe 
TBI [initial Glasgow Coma Score (GCS) ≤8 (41)] followed by a 
prolonged disorder of consciousness (DOC), resulting in level of 
cognitive functioning (LCF) <4 (42) and disability rating scale 
(DRS) >17 (43) at the recruitment time (between 15 and 40 days, 
median 28 days).
Plasma samples collection
Venous peripheral blood samples were collected from patients 
into heparinized tubes and labeled by numeric code. Within 1 h, 
the blood samples were centrifuged at 1500 g, for 15 min at 14°C 
to obtain the plasma and buffy coat from each sample.
The plasma samples from TBI patients were taken for the first 
time (T0) as soon as the clinical signs and the laboratory markers 
(procalcitonin and leukocyte count) confirmed the absence of 
infections, between 15 and 66 days after the TBI (mean ± SEM: 
32.4 ± 3.2 days). This time corresponds to the post-acute phase. 
Oxidative stress parameters and cytokine plasma levels were 
then evaluated two more times, always in absence of clinical 
and/or laboratory signs of infections: at T3, 3 months after T0 
(104–176  days after the TBI, mean ±  SEM: 128.1 ±  3.9) cor-
responding to a late post-acute/early chronic phase, and at T6, 
6  months after T0 (193–296  days after the TBI, mean ±  SEM: 
224.7 ± 5.6) corresponding to the chronic phase.
No patient was taking any anti-inflammatory medication when 
the plasma samples were withdrawn. Samples processing and 
scoring were performed blind at the end of the study. Information 
about clinical status, biochemical data, and immunological data 
were linked to the code number and statistically analyzed.
chemicals and reagents
NADPH, dimethyl sulfoxide (DMSO), 1-chloro-2,4-dinitroben-
zene (CDNB), 5,5′-dithiobis(2-nitrobenzoic) acid (DTNB), 
reduced glutathione (GSH), oxidized glutathione (GSSG), 
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt (WST-1), xanthine oxidase (XO), 
and all other chemicals of the highest analytical grade were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
enzymatic activity assays
Glutathione reductase (GR) activity was measured, as reported 
previously (44). Briefly, 30 μl of plasma was added to 970 μl of 
reaction mix (100  mM phosphate buffer, pH 7.5, containing 
1 mM EDTA, 2 mM NADPH, and 2 mM GSSG). The decrease in 
absorbance at 340 nm was monitored spectrophotometrically for 
1 min at 25°C. GR activity was expressed as units per milliliter. 
One unit of enzyme activity is defined as the amount of enzyme 
that causes the oxidation of 1.0 μmol of NADPH at 25°C at pH 7.5.
Catalase activity from plasma samples was determined 
according to the method of Johansson and Borg (45). The method 
is based on the enzyme reaction with methanol in the presence 
of an optimal concentration of hydrogen peroxide. The for-
maldehyde produced is measured spectrophotometrically with 
4-amino-3-hydrazino-5-mercapto-1,2,4-triazole (Purpald) as a 
chromogen. CAT activity was expressed as nanomoles per minute 
per milliliter.
Superoxide dismutase activity was measured according to the 
method of Peskin and Winterbourn (46). This method allows 
SOD assessment by using a highly water-soluble tetrazolium 
salt, WST-1 that produces a water-soluble formazan dye upon 
reduction with a superoxide anion. The rate of the reduction 
with superoxide anion is linearly related to the XO activity and 
is inhibited by SOD. Therefore, the SOD activity was detected 
by a colorimetric method at 450 nm. Values obtained for each 
sample were compared to the concentration–response curve of 
standard SOD solutions and were expressed as units per milliliter. 
One unit of enzyme activity is defined as the amount of enzyme 
that inhibits the reduction of WST-1 by 50% in a coupled system 
with XO at pH 7.8 at 37°C.
Glutathione peroxidase (GPx) activity was spectrophoto-
metrically measured, as described previously (47). The method 
was based on the reduction of GSSG coupled with the oxidation 
of NADPH. The decrease in absorbance at 340 nm was spectro-
photometrically monitored at 25°C. GPx activity was expressed 
as units per milliliter. One unit of GPx activity was defined as 
the amount of enzyme that catalyzes the reduction of 1 μmol of 
NADPH per minute.
Total plasma antioxidant activity (TEAA) was measured, as 
reported previously (48). The method was based on the ability 
of the antioxidant molecules in the sample to reduce the radical 
cation of ABTS, determined by the decolorization of ABTS+, and 
measured as quenching of absorbance at 740 nm. Values obtained 
for each sample were compared to the concentration–response 
curve of a standard Trolox solution and expressed as millimole of 
Trolox equivalents (TE).
cytokine assessment
Interleukin-1β, IL-6, IFN-γ, and TNF-α plasma levels were 
assessed by Bio-Plex Pro Human Cytokine 4-Plex Assay (Bio-
Rad Laboratories, Hercules, CA, USA). Assays were performed 
following the manufacturer’s instructions (Multi beads assay 
BioPlex, BioRad), and cytokines levels were calculated according 
to the Bio-Plex Cytokine software.
snP Detection
Genomic DNA was extracted from peripheral blood leukocytes, 
as described previously (49).
Apolipoprotein E genotyping for the ϵ4 allele (rs429358, 
rs7412) was performed by TaqMan® SNP genotyping assays 
(Applied Biosystems, Foster City, CA, USA), using a CFX96 
BioRad Real-Time cycler and according the manufacturer’s 
instructions.
clinical and cognitive assessment
Functioning and disability were assessed by functional inde-
pendence measure (FIM) (50) and DRS (43) every month up to 
12 months.
Three months after TBI (T3), as soon as some communication 
skill was restored, and later every 3 months up to 1 year (T6, T9, 
and T12), the subjects were prospectively assessed by a structured 
neuropsychological battery specifically chosen to evaluate the 
cognitive functions after TBI (51).
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The neuropsychological protocol included 16 tests adminis-
tered according to validated procedures. The following domains 
were assessed: global cognitive functioning [Mini-Mental State 
Examination – MMSE (52)]; executive functioning [Tower of 
London (53), Wisconsin Card Sorting Test – WCST (54), letters 
and semantic fluency (55), behavioral assessment of the dysex-
ecutive syndrome – BADS (56), trail making test – TMT (57), 
colored progressive matrix – CPM (58), Block design – WAIS 
(59, 60), Paced Auditory Serial Addition Task – PASAT (61)]; 
memory [Rey Auditory Verbal Learning Test (62), Episodic 
Memory Test (63), and Rey–Osterrieth Complex Figure Test 
(64)]; and attention [Allertness, Go/nogo, and Incompatibility 
from Test of Attentional Performance (65)].
In order to compare the results of different tools, the raw score 
of each neuropsychological test was converted into a standard-
ized z-score. The z-scores were calculated by the mean scores and 
the SD of the normative values from a control population (25). 
Negative z-scores indicate a performance below the average of 
healthy subjects, whereas a z-score greater than 0 indicates an 
above-average performance.
A synthetic index (SI) of each cognitive function (66) for 
individual patient was then calculated. SI was expressed as the 
average of the z-scores of all the tests exploring the same cognitive 
domain, and an overall cognitive performance index (CPI) as the 
general average of all the z-scores.
A CPI higher than −1 meant an overall cognitive performance 
within or near the limits of normality (less than 1 SD), whereas a 
CPI lower than −1 meant an overall cognitive performance more 
than 1 SD below the lower limit of normality.
The CPI was preferred as the main outcome measure because 
it is assumed to be sensitive also to later worsening of the cogni-
tive functioning. According to the CPI score 12  months after 
the TBI (T12), the cohort of patients has been divided in two 
groups with different cognitive outcome: the first group showing 
a T12-CPI higher than −1 was classified as good recovery, while 
the group with T12-CPI lower than −1 was classified as slow to 
recover (SR).
Follow-up analysis
The clinical and cognitive assessment continued up to 
12  months, while the phenotypical variables were assessed at 
three different time: T0: baseline, T3: after 3 months, and T6: 
after 6 months.
Among the 22 subjects enrolled in the study, 1 patient deceased 
(007m12), 1 refused to continue in the study (004f12), and 1 
was transferred to another hospital after 6  months (014m13). 
Nineteen patients completed the clinical and cognitive follow-up 
of 12 months.
statistical analysis
The clinical, cognitive, and biomarkers results were reported as 
mean ± SEM. The cognitive outcome measures (T12-CPI) were 
dichotomized into CPI ≥ −1 and CPI < −1. Analysis of variance 
(ANOVA) was used to compare means as appropriate.
Two-way ANOVA (type I sequential Sum of Squares) and 
Tukey HSD post hoc correction were applied to test a design with 
factors being cognitive outcome and time point of the follow-up.
Linear models fitting and regression lines were used to explore 
predictors of the DRS.
Pearson’s product–moment correlation was also applied to 
correlate plasma levels to cognitive performances in time.
The statistical calculations were conducted using the Statistical 
Package for the Social Sciences (version 20.0; SPSS Inc., Chicago, 
IL, USA) and the R open source software (version 3.2.3; R 
Foundation for Statistical Computing). Significance was defined 
as p ≤ 0.05.
resUlTs
Patient’s demographic and clinical features are described in 
Table  1. Five patients were female. Age and education along 
with the cause of brain injury are detailed for each subject. The 
patient’s age was 38.0 ± 3.09 (mean ± SEM) years, while the years 
of education were 11.4 ± 0.69 (mean ± SEM).
Brain computed tomography (CT) scans results are also 
reported. Localized brain lesions were not seen in five patients, 
five patients had subarachnoid hemorrhage (SAH), and three 
patients had also mesencephalic damages.
At the baseline, approximately 30 days after the TBI, all patients 
were still affected by a severe DOC, with a DRS score ranging from 
18 to 26 (mean ± SEM: 22.3 ± 0.45). All patients had a FIM score 
of 18 (completely dependent on every functional activity) and 
were fed only by nasogastric tube or percutaneous gastrostomy 
with standard commercial products for enteral nutrition.
After 12  months, 2 patients (12m13 and 22m13) were still 
minimally conscious, while 17 patients regained consciousness: 
the outcome ranging from severe disability to good outcome. 
At T12, the FIM score was 88.25 ± 9.47 (mean ± SEM) with 6 
patients who reached the highest scores (120–126) and complete 
independence in daily life activities; the DRS score was 7.3 ± 1.64 
(mean ± SEM).
Between 3 and 9  months after the first assessment, most 
patients reached their best recovery in terms of dependence and 
disability (respectively, FIM and DRS scores).
The average cognitive functioning gradually improved during 
the 12-month follow-up, without sharp differences between the 
three domains (memory, attention, and executive functioning) as 
assessed by the SIs (Figure 1). The largest gain was for memory, 
with significant changes between T3 and T12 (p = 0.016), while 
attention lately worsens (at T12), although the differences did not 
reach statistical significance (Figure 1). The average CPI regularly 
improved from −1.807 at T3 up to −0.811 at T12.
Oxidative stress parameters and cytokine plasma levels were 
evaluated in TBI patients at three time points: at the enrollment in 
the study (T0) corresponding to a post-acute phase, after 3 months 
(T3), corresponding to a late post-acute/early chronic phase and 
6 months (T6) after T0, corresponding to the chronic phase.
In the post-acute phase (T0), GPx and IL6 levels were sig-
nificantly higher than during the chronic phase (T6) (ANOVA 
with post hoc test Tukey HSD, p = 0.0000285 and p = 0.05000, 
respectively); the SOD levels instead were significantly lower 
(p = 0.0189674) (Figure 2). Linear regression analyses for SOD 
(intercept  =  3.18357, slope  =  0.09513, p  =  0.007182), GPx 
(intercept =  0.416538, slope = −0.029617, p =  0.000219), and 
TaBle 1 | clinical and demographic data of TBi subjects.
code gender age education 
(years)
cause of TBi Diffuse 
injury
lesions (cT scans) Decompressive 
craniectomy
skeletal 
trauma
001f12 F 47 13 Road accident Y Right frontal Y Y
002m12 M 61 17 Road accident Y Right frontal, bilateral temporal N N
003f12 F 53 13 Road accident Y Left fronto-temporo-parietal Y N
004f12 F 19 13 Road accident Y Right fronto-temporo-parietal Y Y
005f12 F 20 13 Road accident Y SAH, right mesencephalon N N
006m12 M 19 13 Road accident Y None N Y
007m12 M 54 NA Road accident Y Left occipital-temporal N Y
008f12 F 43 13 Road accident Y Left frontal N N
009m12 M 26 17 Road accident Y Right external and internal capsule, cerebral 
peduncle, thalamus. Bilateral temporal
N N
010m12 M 38 10 Road accident Y SAH. Right Cerebellum. Posterior left 
mesencephalon. Basal ganglia. Right mesial 
temporal. Bilateral fronto-temporal
N N
011m12 M 25 11 Accident at work Y None Y N
012m13 M 30 8 Road accident Y Right fronto-temporal N Y
013m13 M 29 9 Road accident Y None Y Y
014m13 M 45 13 Road accident Y SAH. Fronto-temporal bilateral N N
015m13 M 27 10 Road accident Y SAH. Left frontal Y Y
016m13 M 20 13 Road accident Y None N Y
017m13 M 56 8 Road accident Y Left fronto-parietal, left occipital N Y
018m13 M 64 5 Fall Y Left frontal N Y
019m13 M 29 8 Road accident Y SAH. Bilateral fronto-parietal and temporal-polar. 
Mesencephalon
Y Y
020m13 M 50 13 Road accident Y Left frontal-polar, fronto-parietal, and insula N Y
021m13 M 46 8 Road accident Y Right frontal, right temporal-polar, and internal 
capsule
N Y
022m13 M 35 NA Road accident Y None Y Y
F, female; M, male; Y, yes; N, no; NA, not applicable.
FigUre 1 | improvements in memory, attention, and executive 
functioning during the 12-month follow-up. The results for the domains 
at every time point (T3, T6, T9, and T12) are reported as mean ± SEM of the 
synthetic index, expressed as the average of the z-scores of all the tests 
exploring the same cognitive domain. Measures were obtained from the 
15 subjects who were able to perform the entire neuropsychological battery 
(t-test T3–T12. *p < 0.05).
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IL6 (intercept =  38.852, slope = −3.883, p =  0.03138) showed 
significant time trends during the 6-month follow-up. On the 
contrary, CAT, GR, TAA, IL1β, IFN-γ, and TNF-α did not show 
significant changes from T0 to T6.
TBI patients were then divided into two groups, accord-
ing to the cognitive recovery attained after 12  months: good 
recovery (GR) (CPI > −1) and SR (CPI < −1). The two groups 
of patients differed for several aspects and also for the time 
of recovery: the GR group achieved earlier, approximately 
3  months after TBI, a plateau of improvement in disability 
and dependence (as measured by DRS and FIM scores); the 
SR group reached their plateau, approximately 9 months after 
the TBI (Figure  3).
The inflammatory markers and the oxidative stress-related 
enzymes have been also analyzed by two-way ANOVA in 
relation to different outcome (SR and GR) and controlling 
for interactions of time from injury (T0, T3, and T6). Most 
inflammatory parameters were related to the cognitive out-
come (Figure 4): IFN-γ (p = 0.017), TNF-α (p = 0.0033), IL6 
(p =  0.0170), and IL1β (p =  0.0353). In addition, IL6 plasma 
levels were also associated with differential time from injury 
(p =  0.0342).
Among the oxidative stress, parameters SOD (p = 0.0179) and 
especially GPx (p = 2.63e−06) showed an association with time 
from injury. GPx shows also a possible weak association with 
cognitive outcome (p = 0.065).
It is interesting to note that the disability assessed by the 
DRS score 12  months after the TBI, positively correlated with 
the T0 levels of IFN-γ (Pearson’s product–moment correlation 
0.5229297, p-value 0.0216; regression: R-squared 0.2735, p-value: 
0.028) and TNF-α (Pearson’s product–moment correlation 
0.5648624; regression: R-squared 0.3191, p-value 0.0117) while 
inversely correlated with GPx activity at T0 (Pearson’s product–
moment correlation −0.490876, p-value 0.02797; Regression: 
FigUre 3 | Time course of functional recovery. Average clinical 
measures of disability (DRS, right y-axis, range 0–30: worst score 30) and 
functional independence (FIM, left y-axis, range 18–126: worst score 18) at 
the enrollment (T0) and after 3, 6, 9, and 12 months. The patients are divided 
in two groups, good recovery (GR) and slow to recover (SR) according to the 
cognitive performance index (CPI) as described in Section “Materials and 
Methods.” The GR patients achieve most of the gains in DRS and FIM scores 
within 3 months after the TBI, while the SR patients reach later a plateau, 
approximately 9 months after the TBI.
FigUre 2 | Plasma antioxidant enzyme activities (a) and cytokine levels (B) in patients at different times after TBi. SOD, CAT, GR, GPx activities, and 
TEAA (a) and IL-1b, IL6, IFN-γ, and TNF-α (B) were measured in plasma samples at different times as reported in Section “Materials and Methods.” The activities at 
T0 and after 3 and 6 months are reported. Statistical analysis was performed by one-way ANOVA followed by Tukey HSD post test (*p < 0.05).
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R-squared 0.241, p-value 0.028) (Figure  5). In other words, 
high IFN-γ and TNF-α plasma levels and lower GPx activity in 
the post-acute phase seem to be associated with a poor clinical 
outcome after the 12-month follow-up.
From T3 to T6, when most of the patients (15/19) could 
be tested with the neuropsychological battery, high IL6 
plasma levels seem to hinder the cognitive functioning (CPI) 
(Pearson’s product–moment correlation −0.4363128, p-value 
0.02028) (Table  2). More in detail, higher IL6 plasma levels 
correlated with lower indexes (SI) of executive functioning 
(Pearson’s product–moment correlation −0.5119536, p-value 
0.005354) and attention (Pearson’s product–moment correla-
tion −0.420941, p-value 0.0257), but not with the memory 
index. Similarly, higher plasma levels of IFN-γ and TNF-α 
correlated with lower executive functioning SI (Pearson’s prod-
uct–moment correlation −0.4874287, p-value 0.008516 and 
Pearson’s product–moment correlation −0.4687868, p-value 
0.01186, respectively).
Interestingly, all the TBI subjects were APOE ϵ4 carriers 
(13.6% = ϵ2/4; 86.4% = ϵ3/4), no bias in the recruitment was 
applicable since patients were genotyped for APOE ϵ4 after the 
recruitment.
DiscUssiOn
After a severe TBI, the temporal profile of serum inflamma-
tory markers is not completely characterized, while long-term 
profile of antioxidant related enzyme activity is so far unknown, 
although it is known that oxidative stress plays a role in 
TBI (6, 7).
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FigUre 4 | association between inflammatory markers and oxidative stress-related enzymes with different outcome (sr and gr). Analysis performed 
by two-way between subjects ANOVA (type I sequential Sum of Squares) and Tukey HSD post hoc correction; factors are cognitive outcome and time point of the 
follow-up. Higher plasma levels of IFN-γ (p = 0.017), TNF-α (p = 0.0033), IL6 (p = 0.0170), and IL1β (p = 0.0353) are related to poorer cognitive outcome. Plasma 
levels of GPx (p = 2.63e−06), SOD (p = 0.0179), and IL6 (p = 0.0342) change with time from injury.
Few studies investigated the cytokines blood levels during 
periods longer than 7 days (38, 39), and one report (40) investi-
gated cytokines serum levels 3–6 months after the TBI.
While the enzymes involved in oxidative stress are well 
identified, their imbalance after TBI is not yet determined and 
published data are mainly derived from animal studies (67–71).
A wide number of enzymes are involved in ROS generation. 
Superoxide anion and hydroxyl radical are rapidly formed via the 
enzyme NADPH oxidase and contribute to the oxidative stress 
following TBI (7, 72). Microglial cells are rich in NADPH oxidase 
and ROS produced by microglia can contribute to neuroinflam-
mation by altering mitochondrial dynamics in astrocytes (73), 
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FigUre 5 | relationship between the levels of antioxidant enzyme 
activities and cytokines at the baseline (T0) and the outcome as 
measured by the Drs after 12 months. Simple linear regression models 
relating GPx (R-squared 0.241, p-value 0.028), TNF-α (R-squared 0.3191, 
p-value 0.0117), and IFN-γ (R-squared 0.2735, p-value: 0.028) plasma levels 
at T0 with the overall disability measures at T12.
TaBle 2 | correlation between global cognitive functioning (cPi), 
synthetic index (si) of cognitive domains, and plasma level of cytokines 
and oxidative stress-related enzymes.
cPi aTT MeM eXF
GR 0.11933566 −0.07006214 −0.04412505 0.24945769
SOD −0.01212944 0.06189362 0.16473213 −0.14251454
GPx −0.14166039 −0.22017577 −0.34377650 0.01092828
CAT 0.24253298 0.33661015 0.16366107 0.22153043
TAA 0.06368209 −0.20511358 −0.12738416 0.20721715
IL1β −0.08801661 −0.08321005 −0.01759094 −0.17536462
IL6 −0.4363128* −0.4209410* −0.2213672 −0.5119536*
IFN-γ −0.36136382 −0.30798937 −0.14908328 −0.48742874*
TNF-α −0.36875750 −0.16062906 −0.26462623 −0.46878678*
All the results at T3 and T6 are considered. The CPI and the SIs (ATT, attention; MEM, 
memory; EXF, executive functions) are calculated from the neuropsychological tests 
battery.
Pearson’s product–moment correlation, *p < 0.05.
by amplifying the production of pro-inflammatory cytokines 
(74), and by exerting direct toxic effects on neurons.
Beyond the NADPH oxidase family, both endothelial and 
inducible nitric oxide synthase, cytochrome P450, cycloxygenase, 
lipoxygenase, and XO are involved in mitochondrial dysfunction 
and excitotoxicity (75).
Superoxide dismutase, GPx, and CAT activities contribute to 
an increased level of TEAA.
The sample of patients enrolled in this study are not rep-
resentative of the entire spectrum of TBI severity, since one 
of the inclusion criteria was a persistent DOC at the time 
of the enrollment in the study. These patients with a high 
degree of neurological impairment usually show an uncertain 
clinical outcome and the pattern of recovery is more often 
unpredictable.
The majority of the patients had important clinical improve-
ments during the follow-up, but not all with the same rate 
of recovery. While the cognitive improvement continued for 
at least 12  months, with the possible exception of attention 
that seems to worsen slightly between 9 and 12  months 
after the baseline, most changes in disability and functional 
independence took place within shorter time periods. Some 
patients almost completed their improvements in disability and 
personal independence within 3 months, while others needed 
longer recovery time up to 9 months. Given these differences in 
time, it seemed necessary to set a reliable outcome assessment 
not earlier than 12  months after the enrollment in the study. 
Moreover, the distinction between post-acute and chronic 
phase is blurred since significant individual clinical changes 
occur at different time in different patients. However, it is 
reasonable to assume as post-acute the clinical phase within 
3 months after the TBI. Consequently, T0 falls into the post-
acute phase, T3 into an early chronic phase and T6 into the 
chronic phase.
During the post-acute phase, between 2 and 10  weeks after 
the TBI (T0, median 32  days), oxidative stress-related enzyme 
activities and markers of inflammation were abnormally high if 
compared to previously published data in large populations of 
unaffected subjects (76–78), even in absence of clinical infec-
tions. However, the presence of sub-clinical conditions, such 
as asymptomatic urinary tract infections or other tissue mild 
damages, could not be excluded. These factors might be addi-
tive, rising further the plasma levels of cytokines. These putative 
confounding factors cannot be addressed because of the size of 
patient population.
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Oxidative stress parameters and cytokines plasma levels were 
evaluated in plasma samples at the enrollment in the study (T0), 
after 3 (T3) and 6 months (T6) after TBI. During the post-acute 
phase (T0), GPx activity and IL6 levels were significantly higher 
than during the chronic phase (T6), while, on the contrary, SOD 
activity increased from the post-acute to the chronic phase. CAT 
activity did not change over time. The reasons for these differ-
ences remain unexplained.
In the chronic phase, between 3 and 6  months after the 
enrollment in the study, persistent high plasma levels of 
cytokines appeared to interfere with cognitive functioning, 
with an exception for memory performance. In fact, elevated 
IL-6 plasma levels affected both executive functioning and 
attention, while IFN-γ and TNF-α seem to influence only the 
executive functions. The association between higher plasma IL6 
and lower executive functioning and attention is not specific 
for brain injured individuals since also in healthy middle-aged 
(79) and elderly (80) higher levels of IL6 tend to associate with 
poorer executive functions, but not with memory performances. 
Anyway, in TBI patients, a persistent over-production of IL6, as 
well as of IFN-γ and TNF-α, appear to appreciably change the 
pattern of neuropsychological impairments and time interval of 
cognitive recovery by slowing and unbalancing improvements 
of some domains.
Our findings suggest that the assessment of cytokines profile 
in blood samples may offer a feasible way to investigate long-
term processes affecting slowly recovering patients or to identify 
patients with increased odds of late deterioration.
Oxidative stress and inflammation can affect the TBI clinical 
outcome, but reports concerning antioxidant responses and 
inflammatory markers several weeks after the trauma are still 
scanty. However, this is the time when the patients’ relatives, and 
the clinical teams, stop worrying only about survival and begin 
to wonder about long-term disability. Therefore, any information 
potentially related to cognitive outcome might become clinically 
relevant.
The inflammatory markers and the oxidative stress-related 
enzymes have been analyzed for changes related to different 
cognitive outcome (SR and GR). The inflammatory parameters of 
the post-acute phase (T0) show an intriguing association with the 
cognitive outcome (T12): higher levels of inflammatory cytokines 
(IFN-γ, TNF-α, IL1β, and IL6) at T0 correlated with slower and 
poorer recovery of cognitive functioning 12  months after TBI. 
Also, the functional outcome (in terms of chronic disability after 
12  months) seems to be influenced by higher post-acute (T0) 
levels of IFN-γ and TNF-α.
Differently, the GPx plasma activity at T0 inversely correlates 
with late disability at T12. In other words, higher IFN-γ and 
TNF-α levels and lower GPx activity at baseline seem to increase 
the odds of worse DRS scores 12 months later.
Because GPx activity provides a critical protection against 
lipoperoxide-mediated injury (26), an upregulation during the 
post-acute phase could be critical in the CNS for the oligodendro-
cytes. In fact, these cells are particularly vulnerable to oxidative 
burst because of their low antioxidant enzyme levels (81). A high 
GPx response might promote repair in damaged white matter 
tracts or at least provide a line of defense for myelination. This 
could help to explain the inverse association between the T0 
levels of GPx and the outcome at T12.
With different dynamics, the antioxidant response medi-
ated by SOD gradually increased from T0 to T6. Superoxide 
anions are formed via NADPH oxidase, and this enzyme is 
well represented in microglia cells (72). SOD represents the 
first mechanism of defense against the superoxide and ROS/
RNS levels (82). Because SOD is regulated by its substrate, the 
persistent and increasing upregulation of this enzyme offers 
an indirect proof of increased superoxide production. The 
progressive increase of SOD may be seen as a compensatory 
mechanism, different from the early rise of activity immedi-
ately following the TBI in response to enhanced superoxide 
anion generation (83) because of BBB damages and peripheral 
phagocyte cells activation. Overexpression of extracellular SOD 
in mice has a protective role against brain injury induced by 
chronic hypoxia (84).
On the contrary, CAT did not significantly change over time. 
The reasons for this difference remain unexplained.
Presence of the APOE 4 allele may affect inflammatory 
responses and oxidative stress (85). However, all patients in the 
present investigation were APOE 4 positive, therefore, differential 
influence in inflammatory, oxidative markers, and/or clinical 
outcome cannot be ascribed to this genetic asset.
cOnclUsiOn
Results reported in the present investigation contribute to increase 
the evidence of long-term persistent inflammatory response after 
a severe TBI in humans, and, for the first time, provide clues of 
long-term involvement during the post-acute phase of enzymes 
related to antioxidant activity.
The chronic overexpression of inflammatory cytokines 
interfered with cognitive recovery and mainly affected frontal 
lobe functioning such as the executive functions. Moreover, our 
findings showed that the over-production of cytokines and the 
alteration of the redox homeostasis in the post-acute phases of 
TBI adversely affected the clinical outcome in patients with severe 
neurological damages. The differences between good recovery and 
SR groups (identified according to the CPI at T12) also showed 
that the cognitive outcome might be negatively influenced by 
higher blood profile of cytokine at the baseline (T0). GPx activ-
ity at T0 seemed to influence to some extent the T12 cognitive 
outcome. However, high data variability was observed in patients 
of both groups. The differences in demographic and admission 
characteristics (age, gender, injury details, and CT abnormalities) 
may be considered confounding factors, but the size of the cohort 
did not allow us to perform multivariate statistics. Future studies 
enrolling larger cohorts of patients will be necessary to confirm 
these preliminary observations and to highlight the relation 
between the post-acute cytokine profiles and the most predictive 
factors at admission combined into multivariable prognostic 
models (86).
So far, this new landscape seems very promising for a 
deeper understanding of factors adversely affecting the pro-
cesses of cognitive and motor recovery during the post-acute 
rehabilitation phase. Inflammatory and antioxidant blood 
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